Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-01-28 @ 12:13 PM
Study NCT ID:
NCT02072967
Status:
COMPLETED
Last Update Posted:
2016-02-22
First Post:
2014-02-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Sponsor:
Astellas Pharma Europe B.V.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
RU-BEN-NI-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None